Related Experiment Videos
Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations
Robert Steinfeld1, Alfried Kohlschütter, Johannes Zschocke
1Department of Pediatrics, University of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany.
European Journal of Pediatrics
|August 15, 2002
Insights
Tetrahydrobiopterin (BH(4)) effectively manages phenylalanine levels in infants with BH(4)-responsive phenylalanine hydroxylase deficiency. Adjusting BH(4) dosage alongside protein intake optimizes treatment outcomes.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- Phenylalanine hydroxylase (PAH) deficiency is a genetic disorder.
- Tetrahydrobiopterin (BH(4)) is a cofactor for PAH.
- BH(4)-responsive PAH deficiency requires specific therapeutic strategies.
Observation:
- Three infants with BH(4)-responsive PAH deficiency were studied.
- Varying doses of BH(4) were administered.
- Plasma phenylalanine levels were monitored under controlled protein intake.
Findings:
- BH(4) administration demonstrated a dose-dependent effect on plasma phenylalanine levels.
- Optimized BH(4) dosage correlated with reduced phenylalanine levels.
- Individualized treatment protocols are crucial for managing PAH deficiency.
Implications:
- BH(4) is a viable therapeutic option for BH(4)-responsive PAH deficiency.
- Personalized BH(4) dosing strategies can improve patient outcomes.
- Further research into long-term effects and optimal management is warranted.
Abstract:
The effect of tetrahydrobiopterin (BH(4)) administration was studied in three infants with BH(4) responsive phenylalanine hydroxylase (PAH) deficiency by correlating different BH(4) doses with plasma phenylalanine levels under defined protein intake.